证券代码：688363 证券简称：华熙生物 公告编号：2025-030 华熙生物科技股份有限公司 关于控股股东取得增持股份专项贷款承诺函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 二、贷款承诺函的主要内容 根据华熙昕宇已经取得的招商银行北京分行出具的《贷款承诺函》（编号： 准，招商银行北京分行在总行授权范围内，为华熙昕宇增持公司股票提供不超过 人民币 2.5 亿元的贷款额度，主要要素包括： 借款主体：华熙昕宇投资有限公司 华熙生物科技股份有限公司（以下简称"华熙生物" "公司"）近日收到控股 股东华熙昕宇投资有限公司（以下简称"华熙昕宇"）通知，华熙昕宇已经取得 招商银行股份有限公司北京分行（以下简称"招商银行北京分行"）出具的《贷 （编号：2025 华熙昕宇承诺函 001），招商银行北京分行在总行授权范 款承诺函》 围内，拟为华熙昕宇提供不超过 2.5 亿元人民币的贷款额度，贷款专项用于华熙 昕宇增持华熙生物 A 股无限售条件流通股票，贷款期限不超过 3 年。现将有关 情况公告如下： 一、增持计划的主要内容 ...

证券代码：688363 证券简称：华熙生物 公告编号：2025-030 华熙生物科技股份有限公司 关于控股股东取得增持股份专项贷款承诺函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 华熙生物科技股份有限公司（以下简称"华熙生物""公司"）近日收到控股 股东华熙昕宇投资有限公司（以下简称"华熙昕宇"）通知，华熙昕宇已经取得 招商银行股份有限公司北京分行（以下简称"招商银行北京分行"）出具的《贷 款承诺函》（编号：2025 华熙昕宇承诺函 001），招商银行北京分行在总行授权范 围内，拟为华熙昕宇提供不超过 2.5 亿元人民币的贷款额度，贷款专项用于华熙 昕宇增持华熙生物 A 股无限售条件流通股票，贷款期限不超过 3 年。现将有关 情况公告如下： 一、增持计划的主要内容 华熙昕宇基于对公司未来发展的信心和长期投资价值认可，计划自 2025 年 8 月 8 日起的 6 个月内，使自有资金或自筹资金，通过上海证券交易所系统允许 的方式（包括但不限于集中竞价、大宗交易等）增持公司股份，增持金额不低于 人民币 2 亿元（含） ...

格隆汇8月13日丨华熙生物(688363.SH)公布，近日收到控股股东华熙昕宇投资有限公司（简称"华熙昕 宇"）通知，华熙昕宇已经取得招商银行股份有限公司北京分行出具的《贷款承诺函》，招商银行北京 分行在总行授权范围内，拟为华熙昕宇提供不超过2.5亿元人民币的贷款额度，贷款专项用于华熙昕宇 增持华熙生物A股无限售条件流通股票，贷款期限不超过3年。 ...

人民财讯8月13日电，华熙生物(688363)8月13日晚间公告，控股股东华熙昕宇已经取得招商银行北京分 行出具的《贷款承诺函》，招商银行北京分行在总行授权范围内，拟为华熙昕宇提供不超过2.5亿元的 贷款额度，贷款专项用于华熙昕宇增持华熙生物A股无限售条件流通股票，贷款期限不超过3年。 ...

Core Viewpoint - Huaxi Biological is facing serious allegations of financial misconduct, including accusations of financial fraud and inflated revenue figures, which have led to a significant decline in its stock price and raised concerns about its governance and internal conflicts [3][4][29]. Group 1: Allegations and Responses - A former employee, David, has accused Huaxi Biological's controlling shareholder, Huaxi Xinyu Investment Co., of concealing shareholdings and committing fraud related to bond issuance and revenue inflation [3][4]. - Huaxi Biological has publicly responded, stating that David was previously a market director who committed fraud and was reported for embezzlement [3][24]. - The company claims that David's allegations were investigated during its IPO process in 2019 and were found to be unsubstantiated [3][29]. Group 2: Financial Data Discrepancies - Significant discrepancies in financial data have been highlighted, with David pointing out that the revenue for the first half of 2017 was reported at 278 million RMB, which was 91 times the total revenue for the entire year [11][14]. - The company's financial reports show a dramatic increase in operating income and expenses in 2017, followed by a sharp decline in the annual report, raising red flags about the accuracy of the financial statements [12][20]. - David alleges that the inflated figures were linked to profits from the sale of shares in Jinju Holdings, which were then misclassified as operational costs to reduce tax liabilities [14][16]. Group 3: Internal Conflicts and Governance Issues - Huaxi Biological has faced multiple internal disputes, including allegations of stock buybacks at undervalued prices and conflicts among founding members regarding profit-sharing [34][36]. - The company has been criticized for its governance practices, with frequent reports of employee grievances and accusations of workplace bullying [34][36]. - Recent financial performance has shown a decline, with a reported 11.6% drop in revenue and a 70.6% decrease in net profit for 2024, indicating potential underlying issues within the company [34][36].

Core Insights - The global functional skincare market is projected to reach approximately $180.5 billion in 2024, with China accounting for about 27% of the global skincare market [6][8]. - The market for functional skincare products is expected to grow at a compound annual growth rate (CAGR) of 5%, potentially exceeding $240 billion by 2030 [10]. Industry Overview - The concept of "functional cosmetics" emerged in the 1940s, with the term "pharmaceutical cosmetics" introduced in the 1970s by dermatologist Albert Kligman, leading to widespread acceptance in Western countries [6]. - The functional skincare market is currently dominated by brands from Europe, Japan, and the United States, with significant players including L'Oréal, Estée Lauder, and Shiseido [3]. Market Competition - The global functional skincare market exhibits a moderate level of concentration, with numerous brands competing, although leading companies like L'Oréal and Estée Lauder hold significant market shares [4]. - China's Betaini has a notable competitive advantage in the dermatological skincare segment [3]. Future Projections - The global functional skincare market is expected to grow at a faster rate than the overall skincare market due to the increasing prevalence of sensitive skin issues in major countries [10].

Market Overview - The medical beauty sector experienced a decline of 0.21% on August 13, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Individual Stock Performance - ST Meigu closed at 3.15 with no change, trading volume of 88,100 shares, and a transaction value of 27.62 million yuan [1] - Huaxi Biological closed at 53.60, down 0.09%, with a trading volume of 40,900 shares and a transaction value of 218 million yuan [1] - Aimeike closed at 186.00, down 0.29%, with a trading volume of 32,400 shares and a transaction value of 600 million yuan [1] - Jinbo Biological closed at 301.49, down 0.49%, with a trading volume of 8,955 shares and a transaction value of 271 million yuan [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 63.94 million yuan from institutional investors, while retail investors had a net inflow of 61.61 million yuan [1] - Speculative funds recorded a net inflow of 2.34 million yuan [1] Additional Stock Data - ST Meigu reported a net outflow of 3.73 million yuan, a decrease of 13.52% [2] - Huaxi Biological had a net outflow of 16.99 million yuan, a decrease of 7.78% [2] - Aimeike experienced a net outflow of 43.22 million yuan, a decrease of 7.20% [2]

Summary of Key Points Core Viewpoint - The investment and financing landscape of the medical beauty injection materials industry in China is relatively mature, with a significant number of investment events and a focus on scientific research and technology services. Group 1: Financing Status - As of June 2025, there have been 39 investment events in the medical beauty injection materials industry, indicating a mature investment environment [2][4]. - The majority of financing events are concentrated in Shandong and Jiangsu provinces, with Shandong having 8 events and Jiangsu 7 events [4]. Group 2: External Investment Layout - Representative companies in the medical beauty injection materials industry have engaged in numerous external investment events, primarily focusing on scientific research and technology services, which account for approximately 58% of their investments [14][13]. - Other sectors of investment include manufacturing (18%) and wholesale and retail (8%) [14]. Group 3: Mergers and Acquisitions - The level of mergers and acquisitions in the medical beauty injection materials industry is relatively low, with notable participation from real estate companies. For instance, Lushang Development acquired 100% of Shandong Furuida Pharmaceutical Group in 2018 to enter the medical beauty sector [16].

| 53 | 山东大熊投资控股集团有限公司 | | --- | --- | | 54 | 山东荣信集团有限公司 | | 55 | 山东尚能投资控股集团有限公司 | | 56 | 玲珑集团有限公司 | | 57 | 荣华建设集团有限公司 | | 58 | 银丰投资集团有限公司 | | 59 | 山东远通汽车贸易集团有限公司 | | --- | --- | | 60 | 潍坊特钢集团有限公司 | | 61 | 淄博商厦股份有限公司 | | 62 | 日日顺供应链科技股份有限公司 | | 63 | 青岛国恩科技股份有限公司 | | 64 | 中青建安建设集团有限公司 | | 65 | 山东兴华建设集团有限公司 | | 66 | 青岛康大控股集团有限公司 | | 67 | 山东博汇纸业股份有限公司 | | 68 | 得利斯集团有限公司 | | ea | 山东鑫海科技股份有限公司 | | 70 | 济南圣泉集团股份有限公司 | | 71 | 明泉集团股份有限公司 | | 72 | 潍坊昌大建设集团有限公司 | | 73 | 山东华邦建设集团有限公司 | | 74 | 东营奥星石油化工有限公司 | | 75 | 润华集团 ...

证券之星消息，8月12日医疗美容板块较上一交易日上涨0.16%，*ST美谷领涨。当日上证指数报收于 3665.92，上涨0.5%。深证成指报收于11351.63，上涨0.53%。医疗美容板块个股涨跌见下表： | 代码 | | | 名称 | | | | | --- | --- | --- | --- | --- | --- | --- | | 688363 华熙生物 | 1803.13万 | 5.27% | 900.06万 | 2.63% | -2703.19万 | -7.89% | | 000615 *ST美谷 | 639.16万 | 13.49% | -212.57万 | -4.49% | -426.59万 | -9.00% | | 300896 爱美客 | -176.08万 | -0.27% | 1005.58万 | 1.57% | -829.50万 | -1.29% | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗美容板块主力资金净流入2266.21万元，游资资金净流入1693.07万元，散户 资金 ...